Genotypic analysis of the protease and reverse transcriptase of HIV type 1 subtype C isolates from antiretroviral drug-naive adults in Malawi

被引:21
作者
Petch, LA
Hoffman, IF
Jere, CS
Kazembe, PN
Martinson, FE
Chilongozi, D
Fiscus, SA
Cohen, MS
机构
[1] Univ N Carolina, Ctr AIDS Res, Chapel Hill, NC 27599 USA
[2] Malawai Coll Med, Blantyre, Malawi
[3] Lilongwe Cent Hosp, Lilongwe, Malawi
关键词
D O I
10.1089/aid.2005.21.799
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The protease (PR) and reverse transcriptase (RT) regions of HIV-1 isolates from 21 antiretroviral (ARV)-naive Malawian adults were sequenced and analyzed to determine the prevalence of drug resistance-associated mutations in this population. Phylogenetic analysis confirmed that all isolates grouped with HIV-1 subtype C, the predominant subtype in Malawi. No major mutations associated with resistance to PR inhibitors (PIs), nucleoside RT inhibitors (NRTIs), or nonnucleoside RT inhibitors (NNRTIs) were found. In contrast, accessory mutations were found in the protease region at positions 10, 20, 36, 63, 77, and 93, and in the RT region at positions 118, 211, and 214. Further studies will be needed to determine the clinical impact of these polymorphisms on viral susceptibility to existing antiretroviral drugs.
引用
收藏
页码:799 / 805
页数:7
相关论文
共 21 条
[1]  
[Anonymous], HIV SEQUENCE COMPEND
[2]   Associations between amino acids in the evolution of HIV type 1 protease sequences under indinavir therapy [J].
Brown, AJL ;
Korber, BT ;
Condra, JH .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1999, 15 (03) :247-253
[3]   Resistance-associated mutations in the human immunodeficiency virus type 1 subtype C protease gene from treated and untreated patients in the United Kingdom [J].
Cane, PA ;
de Ruiter, A ;
Rice, P ;
Wiselka, M ;
Fox, R ;
Pillay, D .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (07) :2652-2654
[4]  
CONDRA JH, 1999, ANTIVIR THER, V4, pS44
[5]   Prevalence and conditions of selection of E44D/A and V118I human immunodeficiency virus type 1 reverse transcriptase mutations in clinical practice [J].
Delaugerre, C ;
Mouroux, M ;
Yvon-Groussin, A ;
Simon, A ;
Angleraud, F ;
Huraux, JM ;
Agut, H ;
Katlama, C ;
Calvez, V .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) :946-948
[6]  
ESHLEMAN SH, 2004, J ACQ IMMUN DEF SYND, V1, P126
[7]  
Grossman Z, 2002, ANTIVIR THER, V7, pS39
[8]   A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V [J].
Hertogs, K ;
Bloor, S ;
De Vroey, V ;
Van den Eynde, C ;
Dehertogh, P ;
Van Cauwenberge, A ;
Stürmer, M ;
Alcorn, T ;
Wegner, S ;
Van Houtte, M ;
Miller, V ;
Larder, BA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (03) :568-573
[9]   The emerging genetic diversity of HIV - The importance of global surveillance for diagnostics, research, and prevention [J].
Hu, DJ ;
Dondero, TJ ;
Rayfield, MA ;
George, JR ;
Schochetman, G ;
Jaffe, HW ;
Luo, CC ;
Kalish, ML ;
Weniger, BG ;
Pau, CP ;
Schable, CA ;
Curran, JW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (03) :210-216
[10]   In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: Mutations, kinetics, and frequencies [J].
Jacobsen, H ;
Hanggi, M ;
Ott, M ;
Duncan, IB ;
Owen, S ;
Andreoni, M ;
Vella, S ;
Mous, J .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (06) :1379-1387